Business Context and Reporting Period
This Form 8-K is a current report filed by MEI Pharma, Inc. (not Lite Strategy, Inc.) on June 7, 2013. The filing addresses corporate governance changes, specifically the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Board Appointment: Nicholas Glover, Ph.D., was appointed to the Board of Directors on June 7, 2013.
- Reason for Vacancy: Dr. Glover fills the vacancy created by the retirement of Professor Bryan Williams in May 2013.
- Committee Assignment: Dr. Glover was concurrently appointed to the Compensation Committee.
- Origin of Nomination: The appointment was proposed pursuant to governance agreements entered into on December 18, 2012, with Vivo Ventures Fund VII, L.P. and New Leaf Ventures II, L.P.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of risks and contingencies. Regarding compensation, Dr. Glover will receive standard compensation for non-employee directors and enter into the standard indemnification agreement, as detailed in the Company's Schedule 14A proxy statement filed on October 28, 2011.
Investor Verification Checklist
- Verify the specific terms of the governance agreements with Vivo Ventures Fund VII, L.P. and New Leaf Ventures II, L.P. dated December 18, 2012.
- Review the definitive proxy statement on Schedule 14A (filed October 28, 2011) to confirm the exact standard compensation and indemnification terms for non-employee directors.
- Confirm the press release dated June 11, 2013 (Exhibit 99.1) for additional details on Dr. Glover's background.